BioAge pauses ASCVD program while advancing BGE-102 Phase II
BioAge Labs said it is advancing BGE-102, an NLRP3 inhibitor, into two Phase II trials with early safety and efficacy signals, while pausing its ASCVD program to refocus resources and leverage partnerships and platform/IP strengths.